Sutro Biopharma (FRA:S09) Days Payable : 0.00 (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Days Payable?

Sutro Biopharma's average Accounts Payable for the three months ended in Jun. 2024 was €6.3 Mil. Sutro Biopharma's Cost of Goods Sold for the three months ended in Jun. 2024 was €0.0 Mil.

The historical rank and industry rank for Sutro Biopharma's Days Payable or its related term are showing as below:

FRA:S09's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 134.39
* Ranked among companies with meaningful Days Payable only.

Sutro Biopharma's Days Payable stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00). stayed the same

Sutro Biopharma Days Payable Historical Data

The historical data trend for Sutro Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Days Payable Chart

Sutro Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Sutro Biopharma Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Sutro Biopharma's Days Payable

For the Biotechnology subindustry, Sutro Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sutro Biopharma's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Sutro Biopharma's Days Payable falls into.

Sutro Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Sutro Biopharma's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (4.528	+	8.656)	/	2 )	/	0	*	365
=	6.592					/	0	*	365
=	N/A

Sutro Biopharma's Days Payable for the quarter that ended in Jun. 2024 is calculated as:

	Days Payable (Q: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2024 )	+	Accounts Payable (Q: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2024 )	*	Days in Period
=	( (6.91	+	5.654)	/	2 )	/	0	*	365 / 4
=	6.282					/	0	*	365 / 4
=	N/A

Sutro Biopharma Days Payable Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Sutro Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

STRO:USA S09:Germany

Address

111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.sutrobio.com

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma Headlines

No Headlines